Forty Seven enters trial collaborations with Merck KGAA and Genentech
Forty Seven Inc. entered into trial collaborations with Merck KGAA and Genentech Inc. to evaluate its own antibody Hu5F9G4 as a potential combination therapy for ovarian and bladder cancers and leukemia.
- Trial Collaborations
- R&D (No Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com